Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • ROOMS:

Biotech Stocks on Investors' Radar -- Halozyme Therapeutics, Cara Therapeutics, PDL BioPharma, and Arena Pharma

NEW YORK, April 13, 2017 /PRNewswire/ --

On Wednesday, benchmark US indices were in bearish colors as the NASDAQ Composite closed the trading session down 0.52%; the Dow Jones Industrial Average edged 0.29% lower; and the S&P 500 was down 0.38%. US markets made broad based losses with six out of nine sectors finishing the day in red. Pre-market today, reviews these four Biotechnology stocks: Halozyme Therapeutics Inc. (NASDAQ: HALO), Cara Therapeutics Inc. (NASDAQ: CARA), PDL BioPharma Inc. (NASDAQ: PDLI), and Arena Pharmaceuticals Inc. (NASDAQ: ARNA). Learn more about these stocks by accessing their free research reports at:

Halozyme Therapeutics  

On Wednesday, shares in San Diego, California headquartered Halozyme Therapeutics Inc. recorded a trading volume of 468,997 shares. The stock ended the day 0.87% lower at $12.49. Halozyme Therapeutics' stock has advanced 4.87% in the last three months and 6.21% in the previous one year. The Company's shares are trading above its 200-day moving average by 11.01%. Furthermore, shares of Halozyme Therapeutics, which researches, develops, and commercializes human enzymes and other drug candidates in the US, Switzerland, and internationally, have a Relative Strength Index (RSI) of 40.59. Free research report on HALO is available at:

Cara Therapeutics  

Stamford, Connecticut headquartered Cara Therapeutics Inc.'s stock finished Wednesday's session 3.66% lower at $18.18 with a total volume of 2.08 million shares traded. Over the last one month and the previous three months, Cara Therapeutics' shares have surged 23.59% and 66.94%, respectively. Furthermore, the stock has rallied 144.35% in the past one year. The Company's shares are trading above its 50-day and 200-day moving averages by 10.07% and 80.62%, respectively. Shares of Cara Therapeutics, which focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the US, have an RSI of 56.01.

On March 28th, 2017, research firm Laidlaw reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $20 a share to $35 a share. The complimentary research report on CARA can be downloaded at:

PDL BioPharma  

Incline Village, Nevada headquartered PDL BioPharma Inc.'s stock closed the day flat at $2.03. The stock recorded a trading volume of 1.91 million shares. PDL BioPharma's shares are trading 6.55% and 25.27% below its 50-day and 200-day moving averages, respectively. Shares of the Company, which acquires and manages companies, products, royalty agreements, and debt facilities in the biotech, pharmaceutical, and medical device industries in the US, Europe, and internationally, are trading at a PE ratio of 5.23. Additionally, the stock has an RSI of 40.28. Visit us today and access our complete research report on PDLI at:

Arena Pharma  

On Wednesday, shares in San Diego, California-based Arena Pharmaceuticals Inc. ended the session 0.70% lower at $1.42 with a total volume of 1.03 million shares traded. Arena Pharma's shares have advanced 0.71% in the previous three months. The stock is trading 4.68% below its 50-day moving average and 9.08% below its 200-day moving average. Moreover, shares of the Company, which focuses on developing novel small molecule drugs for various therapeutic areas in the US and Switzerland, have an RSI of 45.80. Get free access to your research report on ARNA at:

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number:  +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Copyright © 2010-2020 & California Media Partners, LLC. All rights reserved.